STAT60%
Federal regulators invite industry, researchers, and lobbyists to closed-door meetings on clinical AI 9%
By Mario Aguilar0%
8/5/2026, 1:05:08 PM
Topics: Artificial Intelligence, Policy
BS Summary: This article contains 2 faulty reasoning types, including In-Group Bias, with Framing Effect as the most egregious example at 37.9% saturation with 72 hits. Analysis detected 116 faulty-reasoning hits from 190 analyzed words, generating a BS Score of 18.9% and a BS Rank of 9% (25,844 of 28,112 articles). This article is better (less manipulative) than 91.90% of the article peer group.
Federal health officials held closed-door conversations with prominent technology companies last month as the health department and its subagencies aim to safely boost adoption of clinical artificial intelligence.
During a “clinical AI demo day” on July 8 at the Food and Drug Administration’s White Oak headquarters, officials from the FDA and the Centers for Medicare and Medicaid Services hosted leaders from 10 companies, according to an agenda for the event reviewed by STAT: Anthropic, Counsel Health, Curai, K Health, Microsoft AI, Amazon One Medical, Doctronic, Ellipsis Health, Hippocratic AI, and Welldoc.
STAT spoke with four companies that attended, Counsel Health, K Health, Hippocratic AI, and Ellipsis Health, whose leaders summarized their comments to regulators.
The meeting was meant to offer federal health officials firsthand experience with AI doctor technology as it exists today.
For the assembled companies, including powerful technology giants and startups funded by influential investors such as Andreessen Horowitz and Khosla Ventures, the event offered a significant opportunity to help shape policy as officials wrestle with regulating health AI and how to pay for it.
Speakers
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.